[3H] Dynorphin can be shown to bind to the brains of both rat and guinea pigs with approximately 50% specific binding. Characterization of the binding in terms of multiple opiate receptor types supports the kappa selectivity of dynorphin in guine~ pig. However, in rat brain, a substantial proportion of the [~H] dynorphin binding is displaced by morphine, suggesting a mu as well as kappa component. Consequently, in rat, dynorphin may show effects at both mu and kappa receptors in vivo.
Dynorphin A 1-17 has been reported to be an endogenous kappa ligand (1,2). However, using in vitro brain bin~ing paradigms, ~ynorphinpshow~ substantial potency in ~om~ng for [~H] morphine or [~H] D-ala--leu ~ enkephalin (DADL) ~binding sites.
Studies in which dynorphin A 1-17 is competed against [~H] kappa ligands usually require blockade or destruction of the mu and delta sites, and subsequent competition against the remaining kappa sites, since completely selective kappa ligands are not available. While this has proven a very useful approach, it may alter a subpopulation of kappa sites which becomes unavailable for study. Consequently there is a need for more direct studies in which dynorphin is used as the radiolabelled ligand and mu, delta and kappa ligands compete with dynorphin for dynorphin binding sites.
The characterization of dynorphin as a kappa ligand is further confounded by the difficulty in demonstating the existence of the kappa receptor. Initial studies in rat brain failed to demonstrate a kappa receptor.
In contrast, studies with guinea pig brain supported the existence of the kappa receptor. More recent work in rat brain by Pfeiffer et al (3) and Chang et al (4) support the existence of a third site called R_ or the benzomorphan site. It is unclear if these two sites correspond to t~e kappa site. We reasoned that some of the discrepancies may be due to s~ecies differences between rat and guinea pig brain. Our own data using [~H] RR2034 suggest twice as many kappa sites in guinea pig brain than in rat brain. This difference in the availability of kappa sites may influence the preference of dynorphin for the kappa opiate receptor in rat versus guinea pi~. To answer these questions we have undertaken the characterization of [~M] dynorphin binding in both rat and guinea pig brain.
METHODS
[3HI dynorphin of high specific activity (50 Ci/mmole) was synthesized by one of us (RH). Binding studies used homogenates of whole brain minus 0024-3205/83 $3.00 + .00 Copyright (c) 1983 Pergamon Press Ltd.
cerebellum.
Brains from both guinea pig and rat were homogenized with a Brinkman Polytron in 0.05 M Tris buffer (pH 7.4 at 25°C) at a concentration of 50 mg tissue/ml buffer.
Brain homogenates were incubated at 37°C for 40 minutes, then centrifugea at 30,000 x g. ~he membrane pellet was resuspended in 0.05 M Tris buffer with ~.2% bovine serum albumen (BSA) at a concentration of 37.5 mg/ml.
[~H] dynorphin was suspended in 0.05 M Tris buffer; the concentration in the assay was 0.5 nM. Nonspecific binding was defined by I uM levorphanol or I uM UMI071
(The active steroisomer of MR2034, a kappa ligand).
Unlabelled oynorphin and UMI071 were added in a small amount (10 microliters) of MeOH-HC1 After a ninety minute incubation period at 0 C, the bound [ H] dynorphin was separated from the free by rapid filtration under vaccuum over ~hatman GF/B glass fiber filters.
The filters were presoaked in 0.05 N Tris buffer with 0.4% BSA and 0.1% polylysine.
Each tube was rinsea with 9 ml of ice cola 0.05 M ~ris buffer with 0.1% BSA, 0.01% Triton X-10~, and 100 mM choline chloride.
Using this procedure, the binding of [aH] dynorphin to filters is reduced to less than 10% of total counts added.
All concentrations
were run in triplicate. Both 3 guinea pig and rat brain studies were run simultaneously using the same [ H] dynorphin and the same competing ligand stocks under the same incubation conditions to assure differences were not due to changes in labelled or unlabelled ligands over t~me. Morphine, DADL, dynorphin A 1-17 and UMI071
were competed against [3H] dynorphin binding to characterize the binding in terms of mu, delta, and kappa receptor preference.
RESULTS
[3H] dynorphin binds with approximately 50% specific binding to both s~ecies.
Both dynorphin A and UMI071 showed substantial ability to displace [~H] dynorphin in rat and guinea pig brain (Table I) . In the case of rat brain, the ICg0 of morphine against [~H] dynorphin is 32 nM, while under the same conditions, the IC~o of morphine in guinea pig brain is 680 nM.
DADL enkephmlin also shows a shift in IC~0 between species, but this is not as dramatic as the morphine shift. However, the ICg n of DADL is quite high in both species suggesting that dynorphin A shows li~le preference for the delta receptor. In contrast, in rat brain, dynorphin A shows more morphine displaceable binding and less kappa selectivity.
The simplest explanation for this species difference is the number of kappa sites available for [ H] Similarly, despite the substantial potency of Beta-endorphin (B-END) at both mu and delta receptors in vitro, destruction of the B-END cell bodies in the arcuate nucleus of the rat produces a selective increase in delta receptors in the thalamus (6) .
Consequently, it is not usually possi- In this case, dynorphin appears to interact with both mu and kappa sites.
DADL vs 3H Dynorphin in Guinea Pig
Since there appear to be fewer kappa sites in rat, it is not surprising that dynorphin may synapse with mu sites as well.
Consequently, there may be pathways in which dynorphin interacts with mu receptors as well as with kappa receptors. Studies comparing the autoradiographic distribution of kappa sites as well as the immunocytochemical distribution of dynorphin should resolve this issue.
